Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Systemic Immunomodulatory Treatments for Atopic Dermatitis
Aaron M. Drucker, Deanna E. Morra, David Prieto‐Merino, et al.
JAMA Dermatology (2022) Vol. 158, Iss. 5, pp. 523-523
Open Access | Times Cited: 114

Showing 1-25 of 114 citing articles:

JAK–STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review
I‐Hsin Huang, Yi‐Teng Hung, Po‐Chien Wu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 132
Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies
Dawn Marie R. Davis, Aaron M. Drucker, Ali Alikhan, et al.
Journal of the American Academy of Dermatology (2023) Vol. 90, Iss. 2, pp. e43-e56
Closed Access | Times Cited: 67
Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis
Eric L. Simpson, Melinda Gooderham, Andreas Wollenberg, et al.
JAMA Dermatology (2023) Vol. 159, Iss. 2, pp. 182-182
Open Access | Times Cited: 65
Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials
Alexandro Chu, Melanie Wong, Daniel Rayner, et al.
Journal of Allergy and Clinical Immunology (2023) Vol. 152, Iss. 6, pp. 1470-1492
Open Access | Times Cited: 54
Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs
Svenja Müller, Laura Maintz, Thomas Bieber
Allergy (2024) Vol. 79, Iss. 6, pp. 1501-1515
Open Access | Times Cited: 44
Optimal Use of Jak Inhibitors and Biologics for Atopic Dermatitis on the Basis of the Current Evidence
Masahiro Kamata, Yayoi Tada
JID Innovations (2023) Vol. 3, Iss. 3, pp. 100195-100195
Open Access | Times Cited: 42
Targeted Systemic Therapies for Adults with Atopic Dermatitis: Selecting from Biologics and JAK Inhibitors
Richard W. Kim, Megan Lam, Katrina Abuabara, et al.
American Journal of Clinical Dermatology (2024) Vol. 25, Iss. 2, pp. 179-193
Closed Access | Times Cited: 18
Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 4, pp. 919-932
Open Access | Times Cited: 17
Real-Life Experience of Tralokinumab for the Treatment of Adult Patients with Severe Atopic Dermatitis: A Multicentric Prospective Study
Axel De Greef, Pierre‐Dominique Ghislain, Audrey Bulinckx, et al.
Clinical Drug Investigation (2023) Vol. 43, Iss. 4, pp. 299-306
Open Access | Times Cited: 23
Real-Life Effectiveness and Tolerance of Upadacitinib for Severe Atopic Dermatitis in Adolescents and Adults
Axel De Greef, Pierre‐Dominique Ghislain, Laurence de Montjoye, et al.
Advances in Therapy (2023) Vol. 40, Iss. 5, pp. 2509-2514
Open Access | Times Cited: 22
Systemic Immunomodulatory Treatments for Atopic Dermatitis
Aaron M. Drucker, Megan Lam, David Prieto‐Merino, et al.
JAMA Dermatology (2024) Vol. 160, Iss. 9, pp. 936-936
Closed Access | Times Cited: 12
Biologic Versus Small Molecule Therapy for Treating Moderate to Severe Atopic Dermatitis: Clinical Considerations
Sneha Butala, Leslie Castelo‐Soccio, Rishi Seshadri, et al.
The Journal of Allergy and Clinical Immunology In Practice (2023) Vol. 11, Iss. 5, pp. 1361-1373
Open Access | Times Cited: 21
Comparative Efficacy of Targeted Systemic Therapies for Moderate-to-Severe Atopic Dermatitis without Topical Corticosteroids: An Updated Network Meta-analysis
Jonathan I. Silverberg, Hwanhee Hong, Brian Calimlim, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 10, pp. 2247-2264
Open Access | Times Cited: 20
First update of the living European guideline (EuroGuiDerm) on atopic eczema
Andreas Wollenberg, Maria Kinberger, B.W.M. Arents, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 37, Iss. 11
Open Access | Times Cited: 19
Living Health Technology Assessment: Issues, Challenges and Opportunities
Praveen Thokala, Tushar Srivastava, Robert Smith, et al.
PharmacoEconomics (2023) Vol. 41, Iss. 3, pp. 227-237
Open Access | Times Cited: 18
JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review
Aishwarya Muddebihal, Ananta Khurana, Kabir Sardana
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 4, pp. 279-295
Closed Access | Times Cited: 17
Safety of Upadacitinib in Immune-Mediated Inflammatory Diseases: Systematic Literature Review of Indirect and Direct Treatment Comparisons of Randomized Controlled Trials
Eduardo Mysler, Gerd R Burmester, Christopher D. Saffore, et al.
Advances in Therapy (2024) Vol. 41, Iss. 2, pp. 567-597
Open Access | Times Cited: 7
Detecting T‐cell receptor clonality in patients with severe atopic dermatitis refractory to dupilumab
Hyung Don Kook, Ho Eun Gwag, So Yun Park, et al.
Journal of the European Academy of Dermatology and Venereology (2024) Vol. 38, Iss. 10, pp. 1939-1946
Closed Access | Times Cited: 6
Comparative Efficacy and Safety of Monoclonal Antibodies and Janus Kinase Inhibitors in Moderate-to-severe Atopic Dermatitis: A Systematic Review and Meta-analysis
Farnam Barati Sedeh, Mattias A. S. Henning, Gregor B. E. Jemec, et al.
Acta Dermato Venereologica (2022) Vol. 102, pp. adv00764-adv00764
Open Access | Times Cited: 23
The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and network meta-analysis
Carlos Alves, Ana Penedones, Diogo Mendes, et al.
European Journal of Clinical Pharmacology (2022) Vol. 78, Iss. 12, pp. 1923-1933
Open Access | Times Cited: 23
S3 guideline Atopic dermatitis: Part 2 ‐ Systemic treatment
Thomas Werfel, Annice Heratizadeh, Werner Aberer, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2023) Vol. 22, Iss. 2, pp. 307-320
Open Access | Times Cited: 15
Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan
Teppei Hagino, Mai Yoshida, Risa Hamada, et al.
Journal of Dermatological Treatment (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 14
Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis
Tiago Torres, A Petersen, Ulla I. Ivens, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 4, pp. 983-992
Open Access | Times Cited: 5
A Multidisciplinary Approach Is Beneficial in Atopic Dermatitis
Paolo Amerio, Silvia Ferrucci, Marco Galluzzo, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 6, pp. 1443-1455
Open Access | Times Cited: 4
Efficacy and safety of systemic targeted therapies for atopic dermatitis in children: A systematic review and meta-analysis
Norio Kawamoto, Hiroki Murai, Kazutaka Nogami, et al.
Allergology International (2025)
Open Access
Page 1 - Next Page

Scroll to top